Schering-Plough has entered into a global collaboration with Novartis AG to develop and commercialize a once-daily inhaled fixed-dose combination therapy for the treatment of asthma and chronic obstructive pulmonary disease (COPD). SP’s once-daily inhaled corticosteroid mometasone (the active ingredient in Asmanex) will be combined with Novartis’ once-daily beta2-agonist indacaterol in a single inhalation device. The combined product, with once-daily dosing, has the potential to...